Suchergebnisse - "Weinreich, David M"

PubPharm (8)

1

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

enthalten in: Scientific reports | 2023

von Li, D. | Xu, M. | Hooper, A. | +9

2

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

enthalten in: The Journal of infectious diseases | 2022

von Somersan-Karakaya, S. | Mylonakis, E. | Menon, V. | +31

3

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

enthalten in: mBio | 2022

von Hooper, A. | Somersan-Karakaya, S. | McCarthy, S. | +12

4

Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting : a retrospective cohort study using a large claims database

enthalten in: BMJ open | 2022

von Hussein, M. | Wei, W. | Mastey, V. | +6

5

Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Stein, D. | Oviedo-Orta, E. | Kampman, W. | +8

6

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

enthalten in: The New England journal of medicine | 2021

von Weinreich, D. | Sivapalasingam, S. | Norton, T. | +138

7

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

enthalten in: The New England journal of medicine | 2021

von O'Brien, M. | Forleo-Neto, E. | Musser, B. | +134

UpdateOf: medRxiv. 2021 Jun 17;:. - PMID 34159344

8

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

enthalten in: The New England journal of medicine | 2021

von Weinreich, D. | Sivapalasingam, S. | Norton, T. | +131

CommentIn: N Engl J Med. 2021 Jan 21;384(3):289-291. - PMID 33471984

1
[1]